Healthcare research

Coiled Therapeutics plc

Ticker: COIL LN

First day of trading on AIM

Non-Independent Research

*SP Angel acts as Nomad and Joint-Broker to the Company

MiFID II Exempt

27 March 2026

Today, Coiled Therapeutics rang the bell at the London Stock Exchange for its first day of trading on AIM under the ticker COIL. Previously known as Roquefort Therapeutics, the Company has raised £8.5m and, concomitantly, acquired the exclusive global licence for AO-252. The newly formed Company positions itself as a newly transformed clinical-stage oncology player centred on precision medicine. AO-252 is a first-in-class, brain-penetrant TACC3 inhibitor that has already shown early signs of tumour reduction and a benign safety profile in Phase I studies. With fresh capital and strong backing from A2A Pharma's investor group, Coiled is expanding the ongoing Phase I trial into prostate and ovarian cancers, expecting meaningful data by Q4 2026. Its website could be accessed following the link: Coiled Therapeutics plc Clinical Stage Oncology Company

Acquisition of the AO-252 license

Roquefort Therapeutics has acquired the exclusive worldwide license for AO-252 from Coiled Therapeutics, Inc. ("Coiled USA"), a spin-out from A2A Pharma, a novel first-in-class drug targeting the TACC3 protein for cancer treatment. The £8.5m (gross) fundraise provides the capital runway to reach key clinical and value inflexion points relating to the development of AO-252 in 2026 and 2027. The Company also intends to progress Roquefort's STAT6 programme into a Phase I clinical trial.

TACC3 inhibitor AO-252

AO-252 is an orally available, first-in-class small molecule that inhibits the TACC3 protein, which plays a critical role in cell division and is often overexpressed in aggressive cancers. By disrupting TACC3's protein-protein interactions, AO-252 induces mitotic & replication stress through impairment of the DNA damage repair process and activation of immunity, leading to cancer cell death, particularly in TP53-mutant cells, while showing minimal toxicity in healthy cells. AO-252 is currently in Phase I clinical trials in the US for advanced solid tumours, with early results demonstrating encouraging efficacy and a benign safety profile. TACC3 overexpression is linked to poor prognosis and increased aggressiveness in a wide range of cancers, making it a promising therapeutic target. Furthermore, its mechanism of action may enable the small molecule to be incorporated into combination therapy protocols, thereby enhancing the anticancer efficacy of existing treatments.

Phase I clinical trial

The Phase I clinical trial for AO-252 is an open-label, first-in-human study targeting advanced solid tumours, with a focus on patients who have TP53-mutated cancers. The trial consists of a dose-escalation phase to assess safety, tolerability, and pharmacokinetics, followed by an expansion cohort to evaluate efficacy in additional tumour types. As of the latest update, AO-252 has already demonstrated tumour reduction of up to 33% in endometrial and 29% in ovarian cancer patients at sub-therapeutic exposure level. The small molecule has also shown a favourable benign safety and tolerability profile to date, contrasting positively with traditional forms of cancer treatment.

Research

Dr Grégoire Pavé
+44 20 3470 0474
greg.pave@spangel.co.uk

Vadim Alexandre
+44 20 3470 0474
Vadim.Alexandre@spangel.co.uk

Sales

Richard Parlons
+44 20 3470 0472
richard.parlons@spangel.co.uk

Grant Barker
+44 20 3470 0471
grant.barker@spangel.co.uk

Rob Rees
+44 20 3470 0535
rob.rees@spangel.co.uk

Abigail Wayne
+44 20 3470 0534
abigail.wayne@spangel.co.uk

Disclaimer – Non-independent Investment Research

This note is a marketing communication and comprises non-independent research. This means it has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of its dissemination.

MiFID: This note may be received free of charge by any person subject to the new MiFID rules on research unbundling pursuant to the exemptions within Article 12(3) of the MiFID Delegated Directive and FCA COBS Rule 2.3A.19.

This note has been issued by SP Angel Corporate Finance LLP ('SPA') in order to promote its investment services. Neither the information nor the opinions expressed herein constitutes, or is to be construed as, an offer or invitation or other solicitation or recommendation to buy or sell investments. The information contained herein is based on sources which we believe to be reliable, but we do not represent that it is wholly accurate or complete. SPA is not responsible for any errors or omissions or for the results obtained from the use of such information. Where the subject of the research is a client company of SPA we may have shown a draft of the research (or parts of it) to the company prior to publication in order to check factual accuracy, soundness of assumptions etc.

No reliance may be placed for any purpose whatsoever on the information, representations, estimates, or opinions contained in this note, and no liability is accepted for any such information, representation, estimate or opinion. All opinions and estimates included in this report are subject to change without notice. This note is confidential and is being supplied to you solely for your information and may not be reproduced, redistributed, or passed on, directly or indirectly, to any other person or published in whole or in part, for any purpose.

In some cases, this research may have been sent to you by a party other than SPA, and, if so, the contents may have been altered from the original, or comments may have been added, which may not be the opinions of SPA. SPA is not responsible for amended research.

The investments discussed in this report may not be suitable for all investors. Investors should make their own investment decisions based upon their own financial objectives and financial resources and it should be noted that investment involves risk. Past performance is not necessarily a guide to future performance and an investor may not get back the amount originally invested. Where investment is made in currencies other than the currency of the investments, movements in exchange rates will have an effect on the value, either favourable or unfavourable.

This note is intended only for distribution to Professional Clients and Eligible Counterparties as defined under the rules of the Financial Conduct Authority and is not directed at Retail Clients, as defined by the rules of the Financial Conduct Authority ("FCA"). SP Angel does not provide broking or investment advisory or management services to individual retail clients.

Distribution of this note does not imply distribution of future notes covering the same issuers, companies, or subject matter.

SPA has put in place a number of measures to avoid or manage conflicts of interest with regard to the preparation and distribution of research. These include (i) physical, virtual, and procedural information barriers (ii) controls on personal account dealing and disclosures of holdings by analysts and (iii) measures to ensure that recipients and persons wishing to access the research receive/are able to access the research at the same time.

You are advised that SPA and/or its partners and employees may have already acted upon the recommendations contained herein or made use of all information on which they are based. SPA is or may be providing or has or may have provided within the previous 12 months, significant advice, or investment services in relation to some of the investments concerned or related investments.

SP Angel Corporate Finance LLP is a company registered in England and Wales with company number OC317049 and its registered office is SP Angel Corporate Finance LLP, 35 – 39 Maddox Street, London, W1S 2PP, United Kingdom.

SP Angel Corporate Finance LLP is Authorised and Regulated by the Financial Conduct Authority whose address is:

25 The North Colonnade, Canary Wharf, London E14 5HS and is a Member of the London Stock Exchange plc.

SP Angel Corporate Finance LLP definition of research ratings:

Expected performance over 12 months: Buy - Expected return of greater than 15%, Hold - Expected return from -15% to +15%, Sell - Expected negative return greater than 15%